NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Where in United States
- Birmingham · University of Alabama at BirminghamUnknown status
- Charleston · Medical University of South Carolina (MUSC)Unknown status
- Chicago · The University of Chicago Medical Center (UCMC)Unknown status
- Cleveland · Cleveland ClinicUnknown status
- Dallas · Mary Crowley Cancer ResearchUnknown status
- Durham · Duke UniversityUnknown status
- Los Angeles · USC / Norris Comprehensive Cancer CenterUnknown status
- Milwaukee · Froedtert Hospital and the Medical College of WisconsinUnknown status
- Nashville · Vanderbilt University Medical CenterUnknown status
- Pittsburgh · University of Pittsburgh Medical Center (UPMC) - Hillman Cancer CenterUnknown status
- Providence · Lifespan Cancer Institute at Rhode Island HospitalUnknown status
The registry text, word for word
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Inclusion: Patients with histologically confirmed, advanced-stage protocol-specified solid tumors; Confirmed ROR1 tumor expression; Patients who have undergone at least one prior systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable or have medical contraindications to standard therapy.
Exclusion: Prior treatment with any agent targeting ROR1 or prior treatment with a CD3 T-cell engaging therapy; Prior treatment with chimeric antigen receptor (CAR) cell therapy within 90 days prior to first dose of NM32-2668; Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of NM32-2668; Wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of NM32-2668, or no recovery from side effects of such prior interventions.